EP 139: Rare disease breakthroughs using tRNA with Michelle Werner, CEO of Alltrna and CEO-Partner of Flagship Pioneering

0:00 Intro to The Genetics Podcast.
01:00 Welcome to Michelle.
02:00 Sstop codon diseases and how are they characterised
03:45 Diseases caused by premature stop codons in haploinsufficient genes.
04:35 The role of transfer RNA technology in finding solutions for premature stop codon diseases.
06:16 How Alltrna is engineering tRNAs which can bind to premature termination codons so healthy coding can be restored.
08:10 The number of different engineered tRNAs required to address the 6,000+ genetic diseases
09:38 How Alltrna aims to deliver precision repair using just 19 amino acids.
12:10 Lipid nanoparticles: Modes of delivery and how to get the technology to the right tissues.
14:20 Major types of delivery, from Adeno-Associated Virus (AVV) to conjugations.
16:30 The development of tRNA as a new therapeutic approach and the latest foundational tools.
18:38 How basket clinical trials in the oncology space are enabling mutation specific therapies.
20:22 Entering into the rare genetic liver disease space with a basket trial approach.
21:40 tRNA opening up a unique opportunity to target multiple rare and ultra-rare diseases.
23:13 Measuring efficacy when using an umbrella approach to stop codon diseases.
26:25 Tackling conversations with the Food and Drug Administration and other health authorities.
29:46 How proving the modality to be safe and effective opens up the possibility to focus on diseases which are less well characterised.
31:18 The importance of patient advocacy groups and industry collaboration for delivering therapies and technologies across different geographies.
32:40 Decision-making, including when to develop inhouse and when to seek external partnerships.
34:42 Key learnings Michelle has brought from large pharma organisations to Alltrna
37:51 Working with patient-led organisations to power development in disease areas where there is less commercial value.
40:21 Why Michelle is so passionate about the work being done at Alltrna and how the tRNA modality can bring new solutions to rare disease families and patients.
41:28 One technology or idea Michelle thinks everyone should keep watching and learn more about.
Please consider rating and reviewing us on your chosen podcast listening platform!
Find out more:alltrna.comrarediseaserenegades.org